Fig. 6: In vivo tumor suppression efficacy of Gi-F-CAA for addressing drug resistance.
From: In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy
a BALB/c nude mice were subcutaneously inoculated with 5 × 106 MCF-7/MDR cells and intravenously administrated with PBS, DOX (3 mg/kg in 100 μL PBS), CPT (3 mg/kg in 100 μL PBS) and Gi-F-CAA (8 mg/kg in 100 μL PBS). b The average tumor growth curves of MCF-7/MDR xenografted mice after treated with PBS, DOX, CPT and Gi-F-CAA over 20 days (n = 6 mice). c MCF-7/MDR tumor tissues were harvested at 20 days post-injection. d MCF-7/MDR tumor weights after treated with PBS, DOX, CPT and Gi-F-CAA over 20 days (n = 6 mice). e BALB/c nude mice were subcutaneously inoculated with 5 × 106 786-O cells and intravenously administrated with PBS, Bevacizumab (5 mg/kg in 100 μL PBS) and Gi-F-CAA (8 mg/kg in 100 μL PBS). f The average tumor growth curves of 786-O xenografted mice after treated with PBS, Bevacizumab and Gi-F-CAA (n = 6 mice). g The individual tumor growth curves of mice in the PBS group, Bevacizumab group and Gi-F-CAA group. P-values were performed with one-way ANOVA followed by post hoc Tukey’s test. Data were expressed as mean ± SD. Source data are provided as a Source Data file.
